• Data from the Phase 3 BE VIVID and BE READY studies show that bimekizumab-treated patients with psoriasis achieved significant skin clearance at week 16, rapid response after one dose, and durability of response up to a year
• Results support the importance of selectively inhibiting IL-17F, in addition to IL-17A, with bimekizumab

August is Psoriasis Awareness Month so we’re shining a spotlight on the disease and how UCB is working to deliver solutions that patients value. 

• The U.S. Food and Drug Administration’s (FDA) approval of CIMZIA® (certolizumab pegol) for use in moderate-to-severe plaque psoriasis marks the entry of UCB into immuno-dermatology
• CIMZIA Phase 3 psoriasis studies demonstrated significant and clinically meaningful improvements in biologic-naïve patients and those previously treated with biologics, with clinical benefit maintained through 48 weeks and the flexibility of two dose regimens that allow for tailored treatment¹